Postmenopausal Bleeding Common in Women With Endometrial Cancer


A meta-analysis finds that postmenopausal bleeding occurs in approximately 90% of women with endometrial cancer.

Evaluation of women with postmenopausal bleeding has the potential to capture as many as 90% of endometrial cancers, according to the results of a meta-analysis published recently in JAMA Internal Medicine.

However, researchers led by Megan A. Clarke, PhD, MHS, of the National Cancer Institute, cautioned that most women with postmenopausal bleeding will not be diagnosed with endometrial cancer.

“Current practice guidelines recommend workup to rule out endometrial cancer among all women with postmenopausal bleeding,” Clarke and colleagues wrote. “Our findings support this recommendation by providing reassurance that targeting this high-risk group of women for early detection and prevention strategies will capture most endometrial cancers.”

Endometrial cancer is the most common gynecologic cancer in developed countries, and the incidence of the disease has increased in recent years. Postmenopausal bleeding is a common symptom of endometrial cancer. With this study, Clarke and colleagues wanted to evaluate the prevalence of postmenopausal bleeding in women with endometrial cancer and the risk for this cancer among women with postmenopausal bleeding.

The researchers reviewed literature on endometrial cancer and postmenopausal bleeding from English-language studies published between 1977 through 2017. The analysis included data from 129 studies that included 34,432 women with postmenopausal bleeding and 6,358 women with endometrial cancer.

Ninety-one percent of women with endometrial cancer had postmenopausal bleeding. There was no significant difference in the prevalence of postmenopausal bleeding by cancer stage. Looking at different geographic regions, the researchers found that the prevalence of postmenopausal bleeding was 94% in North America, and 90% in Western Asia and Eastern Asia.

The overall pooled risk of endometrial cancer among women with postmenopausal bleeding was 9%, according to the study. This risk increased to 12% when the data were limited to those studies that excluded women using hormone therapy.

“Use of hormone therapy affects this association at multiple levels,” the researchers explained. “Certain combined formulations of estrogen plus progestin therapy are established to have a protective effect on the endometrium. Furthermore, irregular uterine bleeding is a common adverse effect of hormone therapy, particularly within the first 6 months of use.”

Risk for cancer in women with postmenopausal bleeding was lowest in North America (5%) and highest in Western Europe (13%).

“The widespread practice of referring all women with postmenopausal bleeding for transvaginal ultrasound and/or endometrial biopsy carries a considerable burden and cost,” the researchers wrote. “Given the rise in endometrial cancer incidence and mortality, our findings raise the important question of how to best manage postmenopausal bleeding to optimize the benefit of early detection approaches while avoiding unnecessary harms.”

In an editorial published with the study, Kristen A. Matteson, MD, MPH, of Women and Infants Hospital in Providence, Rhode Island, and colleagues applauded the study authors for conducting a study that should “inform both research and clinical care delivery.”

Maurie Markman, MD, president of the Cancer Treatment Centers of America in Boca Raton, Florida, believes the results of this meta-analysis are important.

“This analysis is relevant as it provides a relatively simple summary for physicians seeing women with postmenopausal bleeding with the potential for the underlying condition to be endometrial cancer. In the diagnostic decision process it is relevant to appreciate that approximately 90% of women with endometrial cancer will experience postmenopausal bleeding, but that conversely only about 10% of women with postmenopausal bleeding are ultimately found to have endometrial cancer,” he told Cancer Network.

Related Videos
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Related Content